*in vitro*, *in vivo* -
UK practice generally favours an individualised approach rather than routine cessation
Instead, in obesity, we're differentially investing in MariTide and a number of preclinical assets," Jay Bradner, Amgen's chief scientific officer, said during an earnings call Thursday
Often, they are irregular in shape, but they also may be symmetrical and round
Circulation (2017) 136:20857
Less Common or Severe Side Effects While rare, other treatment-emergent adverse events have been observed: Vomiting, particularly in patients prone to gastrointestinal sensitivity Dizziness or a strange feeling shortly after administration Darkening of skin or gums, attributed to the peptides melanocortin action Mild allergic reaction (e.g., itching, rash, or swelling) These adverse events are more likely to occur in patients who are highly sensitive to neuropeptides or who have pre-existing health conditions affecting metabolism or vascular response